The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer

Ca-A Cancer Journal for Clinicians

Volumn 46, Issue 3, 1996, Pages 142-164

  Appelbaum, Frederick R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CRYOPRESERVATION; DONOR; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TESTIS CANCER;

EID: 0029941186     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.46.3.142     Document Type: Review

References (181)

1. Jacobson LO, Marks EK, Robson MJ, et al: Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med 1949;34:1538-1543.
2. Lorenz E, Uphoff D, Reid TR, Shelton E: Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197-201.
3. Ford CE, Hamerton JL, Barnes DWH, Loutit JF: Cytological identification of radiation-chimaeras. Nature 1956;177:452-454.
4. Thomas ED, Lochte HL Jr, Cannon JH, et al: Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959; 38:1709-1716.
5. Thomas ED, Collins JA, Herman EC Jr, Ferrebee JW: Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962;19:217-228.
6. Gatti RA, Meuwissen HJ, Allen HD, et al: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2:1366-1369.
7. Thomas ED, Storb R, Clift RA, et al: Bone-marrow transplantation. N Engl J Med 1975;292:832-843,895-902.
8. Appelbaum FR, Herzig GP, Ziegler JL, et al: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85-95.
9. Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoieticstem cells. Science 1988;241:58-62.
10. Lord BI, Schofield R: Haemopoietic spleen colony-forming units, in Potten CS, Hendry JH (eds): Cell Clones: Manual of Mammalian Cell Techniques. London. Churchill Livingstone, 1985, pp. 13-26.
11. Clark BR, Gallagher JT, Dexter TM: Cell adhesion in the stromal regulation of haemopoiesis. Baillieres Clin Haematol 1992;5:619-652.
12. Appelbaum FR, Herzig GP, Graw RG, et al: Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. Transplantation 1978;26:245-248.
13. Beatty PG, Clift RA, Mickelson EM, et al: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765-771.
14. Anasetti C, Amos D, Beatty PG, et al: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-204.
15. O'Reilly RJ, Dupont B, Pahwa S, et al: Reconstitution in severe combined immunodeficiency by transplantation of bone marrow from an unrelated donor. N Engl J Med 1977;297:1311-1318.
16. Hansen JA, Clift RA, Thomas ED, et al: Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-567.
17. McCullough J, Hansen J, Perkins H, et al: The National Marrow Donor Program: How it works, accomplishments to date. Oncology 1989;3:63-72.
18. Beatty PG, Hansen JA, Longton GM, et al: Marrow transplantation from HLA-malched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51:443-447.
19. Kernan NA, Bartsch G, Ash RC, et al: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
20. Bast RC Jr, DeFabritiis P, Lipton J, et al: Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45:499-503.
21. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-1533.
22. Rowley SD, Jones RJ, Piantadosi S, et al: Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989;74:501-506.
23. Gorin NC, Aegerter P, Auvert B, et al: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990;75:1606-1614.
24. Chang J, Morgenstern GR, Coutinho LH, et al: The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: An update. Bone Marrow Transplant 1989;4:5-9.
25. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
26. Brenner MK, Rill DR, Moen RC, et al: Genemarking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-86
27. Labopin M, Gorin NC: Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: A retrospective study. Leukemia 1992;6(suppl 4):95-99
28. Cavins JA, Scheer SC, Thomas ED, Ferrebee JW: The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80 C. Blood 1964;23:38-43.
29. Appelbaum FR: Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions. Exp Hematol 1979:7(Suppl 5):7-11.
30. Kessinger A, Armitage JO, Landmark JD, et al: Autologous peripheral hematopoictic stem cell transplantation restores hemalopoietic function following marrow ablative therapy. Blood 1988;71: 723-727.
31. Richman CM, Weiner RS, Yankee RA: Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039
32. Socinski MA, Cannistra SA, Elias A, et al: Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1:1194-1198.
33. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2:580-585.
34. Bensinger W, Singer J, Appelbaum F, et al: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-3163.
35. Pettengell R, Morgenstern GR, Woll PJ, et al: Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993;82:3770-3777.
36. Weaver CH, Buckner CD, Longin K, et al: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993;82:1981-1984.
37. Buckner CD, Clift RA, Sanders JE, et al: Marrow harvesting from normal donors. Blood 1984;64:630-634.
38. Bensinger WI, Longin K, Appelbaum F, et al: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-831.
39. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-1778.
40. Advani R, Chao NJ, Horning SJ, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992;116:183-189.
41. Nemunaitis J, Buckner CD, Appelbaum FR, et al: Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991;77:2065-2071.
42. Hill HF, Chapman CR, Kornell JA, et al: Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 1990;40:121-129.
43. Shulman HM, Hinterberger W: Hepatic venoocclusive disease: Liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
44. McDonald GB, Hinds MS, Fisher LD, et al: Venocclusive disease of the liver and multi-organ failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118: 255-267.
45. 1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993;84:724-730.
46. Bearman SI, Shuhart MC, Hinds MS, McDonald GB: Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992;80:2458-2462.
47. Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after marrow transplantation. Am Rev Respir Dis 1993;147:1393-1400.
48. Chao NJ, Duncan SR, Long GD, et al: Corticosteroid therapy for diffuse alveolar hemorrhage in aulologous bone marrow transplant recipients. Ann Intern Med 1991;114:145-146.
49. Sanders JE, Pritchard S, Mahoney P, et al: Growth and development following marrow transplantation for leukemia. Blood 1986;68:1129-1135.
50. Sanders JE: The impact of marrow transplant preparative regimens on subsequent growth and development: The Seattle Marrow Transplant Team. Semin Hematol 1991;28:244-249.
51. Sanders JE, Buckner CD, Leonard JM, et al: Late effects on gonadal function of cyctophosphamide, total-body irradiation, and marrow transplantation. Transplantation 1983;36:252-255.
52. Sanders JE, Buckner CD, Amos D, et al: Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988; 6:813-818.
53. Deeg HJ, Flournoy N, Sullivan KM, et al: Cataracts after total body irradiation and marrow transplantation: A sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 1984;10:957-964.
54. Rabinowe SN, Neuberg D, Bierman PJ, et al: Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993;81:1903-1908.
55. Torok-Storb B, Fries B, Stachel D, Khaira D: Cytomegalovirus: Variations in tropism and disease. Leukemia 1993;7:583-585.
56. Knox KK, Carrigan DR: In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis 1992; 165:925-929.
57. Storb R, Deeg HJ, Appelbaum FR, et al: The biology of graft rejection in a canine model of marrow transplantation. Transplant Proc 1987;19(suppl 7):18-22.
58. Storb R, Prentice RL, Thomas ED: Marrow-transplantation for treatment of aplastic anemia: An analysis of factors associated with graft rejection. N Engl J Med 1977;296:61-66.
59. Storb R, Prentice RL, Thomas ED, et al: Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983;55:573-585.
60. Champlin RE, Horowitz MM, van Bekkum DW, et al: Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood 1989;73:606-613.
61. Torok-Storb B, Simmons P, Przepiorka D: Impairment of hemopoiesis in human allografts. Transplant Proc 1987;19(6 suppl 7):33-37.
62. Nemunaitis J, Singer JW, Buckner CD, et al: The use of reeombinant human granulocyte-macrophage colony-stimulating factor in graft failure after hone marrow transplantation. Blood 1990;76:245-253.
63. Storb R, Weiden PL, Sullivan KM, et al: Second marrow transplants in patients with aplastic anemia rejecting the first graft: Use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987;70:116-121.
64. Bolger GB, Sullivan KM, Storb R, et al: Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986;1:21-30.
65. Sullivan KM: Graft-versus-hosl disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, Blackwell Scientific Publications, 1994, pp 339-362.
66. Anasetti C, Beatty PG, Storb R, et al: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
67. Nash RA, Pepe MS, Storb R, et al: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosponne and methotrexate. Blood 1992; 80:1838-1845.
68. Storb R, Deeg HJ, Fisher L, et al: Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials. Blood 1988;71:293-298.
69. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-735.
70. Storb R, Deeg HJ, Pepe M, et al: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989;73:1729-1734.
71. Goldman JM, Gale RP, Horowitz MM, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
72. Martin PJ, Hansen JA, Torok-Storb B, et al: Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-456.
73. Champlin R, Ho W, Gajewski J, et al: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease alter allogeneic bone marrow transplantation. Blood 1990;76:418-423.
74. Soiffer RJ, Bosserman L, Murray C, et al: Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990;75:2076-2084.
75. Martin PJ, Schoch G, Fisher L, et al: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990;76:1464-1472.
76. Martin PJ, Schoch G, Fisher L, et al: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991; 77:1821-1828.
77. Anasetti C, Martin PJ, Hansen JA, et al: A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990;50:49-54.
78. Anasetti C, Martin PJ, Storb R, et al: Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992;54:844-851.
79. Sullivan KM, Agura H, Anasetti C, et al: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259.
80. Atkinson K, Horowitz MM, Gale RP, et al: Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-2464.
81. Sullivan KM, Witherspoon RP, Storb R, et al: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72:555-561.
82. Sullivan KM, Witherspoon RP, Storb R, et al: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-554.
83. Vogclsang GB, Farmer ER, Hess AD, et al: Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med 1992;326:1055-1058.
84. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections-in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
85. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
86. Bensinger WI, Price TH, Dale DC, et al: The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-1888.
87. Petersen FB, Buckner CD, Clift RA, et al: Prevention of nosocomial infections in marrow transplant patients: A prospective randomized comparison of systemic antibiolics versus granulocyte transfusions. Infect Control 1986;7:586-592.
88. Petersen F, Thornquist M, Buckner C, et al: The effects of infection prevention regimens on early infectious complications in marrow transplant patients: A four arm randomized study. Infection 1988;16:199-208.
89. Bowden RA, Savers M, Flournoy N, et al: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cylomegalovirus infection alter marrow transplantation. N Engl J Med 1986;314:1006-1010.
90. Goodrich JM, Mori M, Gleaves CA, et al: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-1607.
91. Goodrich JM, Bowden RA, Fisher L, et al: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-178.
92. Meyers JD, Wade JC, Mitchell CD, et al: Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutuneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73:229-235.
93. Meyers JD, Wade JC, Shepp DH, Newton B: Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984;37:571-574.
94. Biggs JC, Horowitz MM, Gale RP, et al: Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-1093.
95. Forman SJ, Schmidt GM, Nademanee AP, et al: Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991;9:1570-1574.
96. Clift RA, Buckner CD, Thomas ED, et al: The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987;2:243-258.
97. Appelbaum FR, Clift RA, Buckner CD, et al: Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 1983;61:949-953.
98. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992;10:1723-1729.
99. Thomas HD, Buckner CD, Clift RA, et al: Marrow transplantation tor acute nonlymphoblaslic leukemia in first remission. N Engl J Med 1979;301:597-599.
100. Blume KG, Beutler E, Bross KJ, et al: Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980;302: 1041-1046.
101. Appelbaum FR, Dahlberg S, Thomas ED, et al: Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia: A prospective comparison. Ann Intern Med 1984;101:581-588.
102. Appelbaum FR, Fisher LD, Thomas ED: Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: A five-year follow-up. Blood 1988;72:179-184.
103. Champlin RE, Ho WG, Gale RP, et al: Treatment of acute myelogenous leukemia: A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985;102:285-291.
104. Marmont A, Bacigalupo A, Van Lint MT, et al: Bone marrow transplantation versus chemotherapy alone for acute nonlymphoblastic leukemia. Exp Hematol 1985;13(suppl 17):40.
105. Zander AR, Kealing M, Dicke K, et al: A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol 1988;6:1548-1557.
106. Coude E, Iriondo A, Rayon C, et al: Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myclogcnous leukaemia in first remission: A prospective controlled trial. Br J Haematol 1988;68:219-226.
107. Reiffers J, Gaspard MH, Maraninchi D, et al: Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: A prospective controlled trial. Br J Haematol 1989; 72:57-63.
108. Ringden O, Bolme P, Lonnqvist B, et al: Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden. Pediatr Hematol Oncol 1989;6:137-144.
109. Dahl GV, Kalwinsky DK, Mirro J Jr, et al: Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults wilh acute nonlymphocytic leukemia in first remission. J Clin Oncol 1990;8:295-303.
110. Schiller GJ, Nimer SD, Territo MC, et al: Bone-marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41-46.
111. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924-1930.
112. Amatlori S, Testi AM, Arico M, et al: Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myclogenous leukemia. J Clin Oncol 1993;11:1046-1054.
113. Nesbit ME Jr, Buckley JD, Feig SA, et al: Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the childrens cancer group. J Clin Oneol 1994;12:127-135.
114. Archimbaud E, Thomas X, Michallet M, et al: Prospective genetically randomized comparison between intensive postinduction chemotherapy and hone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994;12:262-267.
115. Hewlett J, Kopecky JK, Head D, et al: A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study. Leukemia 1995;9:562-569.
116. Yeager AM, Kaizer H, Santos GW, et al: Autologous hone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141-147.
117. Lowenberg B, Verdonck LJ, Dekker AW, et al: Autologous bone marrow transplantation in acute myeloid leukemia in lirsi remission: Results of a Dutch prospective study. J Clin Oncol 1990;8:287-294.
118. Chao NJ, Stein AS, Long GD, et al: Busulfan/etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 1993;81:319-323.
119. Ball ED, Mills LE, Cornwell GG 3d, et al: Autologous hone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 1990;75:1199-1206.
120. Petersen FB, Lynch MH, Clift RA, et al: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993;11:1353-1360.
121. Zittoun R, Mandelli F, Willemze R, et al: Prospective phase III study of autologous hone marrow transplantation (ABMT) v short intensive chemotherapy (IC) v allogeneic bone marrow transplantation (ALLO-BMT) during first complete remission (CR) of acute myelogenous leukemia (AML): Results of the EORTC-GIMEMA AML 8A trial. Blood 1993;82(suppl 1):85a. Abstract.
122. Brochstein JA, Kernan NA, Groshen S, et al: Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987;317:1618-1624.
123. Zwaan FE, Hermans J, Barrett AJ, Speck B: Bone marrow transplantation for acute lymphoblastic leukaemia: A survey of the European Group for Bone Marrow Transplantation (EGBMT). Br J Haematol 1984;58:33-42.
124. Barrett AJ, Horowitz MM, Pollock BH, et al: Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;19:1253-1258.
125. Doncy K, Buckner CD, Kopecky KJ, et al: Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission. Bone Marrow Transplant 1987;2:355-363.
126. Barrett AJ, Horowitz MM, Gale RP, et al: Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989;74:862-871.
127. Chao NJ, Forman SJ, Schmidt GM, et al: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991;78:1923-1927.
128. Horowitz MM, Messerer D, Hoelzer D, et al: Chemotherapy compared with hone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-18.
129. Fiere D, Lepage E, Sebban C, et al: Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11:1990-2001.
130. Barrett AJ, Horowitz MM, Ash RC, et al: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992;79:3067-3070.
131. Kersey JH, Weisdorf D, Nesbit ME, et al: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 1987;317:461-467.
132. Sanz GF, Sanz MA, Vallespì T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
133. Appelbaum FR, Barrall J, Storh R, et al: Bone marrow transplantation for patients with myelodysplasia: Pretreatment variables and outcome. Ann Intern Med 1990;112:590-597.
134. Anderson JE, Appelbaum FR, Fisher LD, et al: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-681.
135. O'Donnell MR, Nademanee AP, Snyder DS, et al: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987;5:1822-1826.
136. Champlin R, McGlave P: Allogeneic bone marrow transplantation for chronic myeloid leukemia, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, Blackwell Scientific Publications, 1994.
137. Thomas ED, Clift RA, Fefer A, et al: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155-163.
138. Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 1989;73:861-864.
139. Goldman JM, Szydlo R, Horowitz MM, et al: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235-2238.
140. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993;82:1954-1956. Editorial.
141. McGlave P, Bartsch G, Anasetti C, et al: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 1993;81:543-550.
142. Lanino E, Anasetti C, Longton G, et al: Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors. Blood 1993;82:344a. Abstract.
143. McGlave PB, De Fabritiis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 1994;343:1486-1488.
144. Michallei M, Corront B, Hollard D, et al: Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases: Report from the EBMTG. Bone Marrow Transplant 1991;7:275-279.
145. Rabinowe SN, Soiffer RJ, Gribben JG, et al: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronie lymphocytic leukemia. Blood 1993;82:1366-1376.
146. Appelbaum FR, Sullivan KM, Buckner CD, et al: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5:1340-1347.
147. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316:1493-1498.
148. Goldstone AH, McMillan AK, Chopra R: High-dose therapy for the treatment of nonHodgkin's lymphoma, in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore, Williams & Wilkins, 1992, pp. 662-676.
149. Chopra R, Goldstone AH, Pearce R, et al: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992;10:1690-1695.
150. Gulati SC, Shank B, Black P, et al: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6:1303-1313.
151. Nademanee A, Schmidt GM, O'Donnell MR, et al: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 1992;80:1130-1134.
152. Verdonck LF, Dekker AW, deGast GC, et al: Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992;10:644-646.
153. Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation (ABMT) with sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first complete remission: A study on 464 patients (LNH87 protocol). Blood 1993;82(suppl 1):87a. Abstract.
154. Takvorian T, Canellos GP, Ritz J, et al: Prolonged disease-free survival after autologous bone marrow transplantation in patients with nonHodgkin's lymphoma with a poor prognosis. N Engl J Med 1987;316:1499-1505.
155. Jagannath S, Dicke KA, Armitage JO, et al: High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986;104:163-168.
156. Armitage JO, Bierman PJ, Vose JM, et al: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991;91:605-611.
157. Jones RJ, Piantadosi S, Mann RB, et al: Highdose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990;8:527-537.
158. Jagannath S, Armitage JO, Dicke KA, et al: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous hone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989;7:179-185.
159. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993;11:2342-2350.
160. Gahrton G, Tura S, Ljungman P, et al: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-1273.
161. Bensinger WI, Buckner CD, Clift RA, et al: Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992;10:1492-1497.
162. Barlogie B, Alexanian R, Dicke KA, et al: High-dose chemoradiotherapy and autologous hone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869-872.
163. Barlogie B, Gahrton G: Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1991;7:71-79.
164. Anderson KC, Barut BA, Ritz J, et al: Monoclonal antibody-purged aulologous hone marrow transplantation therapy for multiple myeloma. Blood 1991;77:712-720.
165. Jagannath S, Vesole DH, Glenn L, et al: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992;80:1666-1672.
166. Attal M, Harousseau IL, Stoppa AM, et al: High dose therapy in multiple myeloma: A prospective randomized study of the Intergroupe Francais du Myelome (IFM). Blood 1993;82(suppl 1):198a. Abstract.
167. Pole JG, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991;9:152-158 [Erratum. J Clin Oncol 1991;9:1094].
168. Philip T, Bernard JL, Zucker JM, et al: High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987;5:266-271.
169. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988;6:1368-1376.
170. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10:102-110.
171. Williams SF, Mick R, Desser R, et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989;7:1824-1830.
172. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous hone marrow transplantation for breast cancer patients with ≥10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 1992;23:1021-1026.
173. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-1143.
174. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992;117:124-128.
175. Nichols CR, Andersen J, Lazarus HM, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10:558-563.
176. Broxmeyer HE, Kurtzberg J, Gluckman E, et al: Umbilical cord hlood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 1991;17:313-329.
177. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991;77:1660-1665.
178. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990;76:1867-1871.
179. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1985;85:1122-1131.
180. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
181. Truitt RL, Atasoylu AA: Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991;77:2515-2523.